Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis - Test2 - elhamkhani - TriplyDB

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis

http://www.wikidata.org/entity/Q28343401

about

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses The role of pro-resolution lipid mediators in infectious disease Resistance to melanoma metastases in mice selected for high acute inflammatory response Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins Lipoxins in chronic inflammation Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.Lipoxin a(4) attenuates microvascular fluid leak during inflammation The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection.Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes A novel rat lipoxin A4 receptor that is conserved in structure and function.A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium Resolvins and protectins in inflammation resolution.Deletion of the aryl hydrocarbon receptor enhances the inflammatory response to Leishmania major infection Aspirin triggered lipid mediators: novel inhibitors of leucocyte trafficking Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression.Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes Lipoxins induce actin reorganization in monocytes and macrophages but not in neutrophils: differential involvement of rho GTPases.Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst.Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation?beta(2)-Adrenergic receptor-dependent sexual dimorphism for murine leukocyte migration.Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii.Antimicrobial peptide scolopendrasin VII, derived from the centipede Scolopendra subspinipes mutilans, stimulates macrophage chemotaxis via formyl peptide receptor 1.Therapeutic Targets for Management of Periodontitis and Diabetes Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators The use of rodent models to investigate host-bacteria interactions related to periodontal diseases.Anti-inflammatory and proresolving lipid mediators.A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.Lipoxins: resolutionary road.Genetics of infectious diseases: hidden etiologies and common pathways.Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer.DNA sequence variation and regulation of genes involved in pathogenesis of pulmonary tuberculosis.Lipid mediators in immune dysfunction after severe inflammation.Resolution of inflammation: targeting GPCRs that interact with lipids and peptides.Fundamentals of and Critical Issues in Lipid Autacoid Medicine: A Review.

P2860

Q24652940-3E563B56-9C3B-49A4-AA2F-83BE708C36EC Q24676421-2200870D-10BD-4679-B31F-DDB88000DD10 Q24685948-B888C0E2-3847-46A8-B8AB-BFFC7DA56B8E Q26863204-A6D41051-5524-49CD-B28D-2217B23EF0F1 Q28175948-4C77B5EB-1674-441E-A326-382AC15BFC46 Q28182535-01A2572C-3B34-456F-91DD-349122FB997F Q28196238-39FFC85A-7B3F-4B2D-A094-F0D46F7C71E1 Q28206660-A5F7DE86-74C9-44CE-8E71-996E18CCF013 Q28394219-DE052A10-F963-4E91-BFAA-05642BB693E6 Q31134484-0DE6013E-40B3-4CC3-ABD2-5160B015E185 Q33831917-CEE1B649-A11B-4B7F-9273-851A40B57BAA Q34160432-24FFD22F-5A3E-4BA4-A7DE-CCD5C8F60E7B Q34482353-F4A25A93-7857-479D-BAAB-04C3A36EA9BA Q34491175-57E402CE-FDDC-4D01-AB71-18B862F380C2 Q34955621-01D95B10-933D-4E08-8353-D6B9118C2A04 Q35045249-9410A6BE-162F-413D-B5BD-E1C903A6CA94 Q35114951-15473AD1-BC65-46E5-A5E1-3CB7BCAAD12D Q35332873-E581EEC7-01CC-4D1A-9BA7-09958A40B555 Q35565135-2F8ABE33-E725-41B8-9472-4C2DC2F2990A Q35577366-F980D99A-E589-4120-9CFC-9175159EE15B Q35633812-E82A4F01-555A-4527-8172-85850BEE6A40 Q35734691-DE940EAC-3AA6-4946-A724-66DA76C9C345 Q35747915-FEE5C54A-7446-47B0-BBA8-03911171C54E Q35865405-65813630-9769-4A78-9831-3CCDBB19BA7B Q35881906-54987281-4811-4B29-B5E5-DD36E7F760FC Q36013500-81F5A01E-37F9-40DA-8296-8A1DCFC1B105 Q36015869-EF235A19-15A2-44AA-91AE-19208AFED609 Q36078499-4F3AC706-8431-4721-9FDC-F6FAC6F1944C Q36863273-FDB2FBD2-C955-461D-A228-70D6E29B7963 Q36879456-B02B23E5-05AB-4225-99A7-0045D5C12EC2 Q37058550-CF421E47-9C7F-4A1B-B26B-DD950FE67BF1 Q37071968-B672B78B-057E-43B5-B7F3-016001C8EAEC Q37591768-16FF31DA-21E8-41F2-8067-19AB381FE7E5 Q37604436-898F87F6-98B0-43F4-8AFC-41E4EFAB56C6 Q37880890-DAC1CFEE-CC2C-41F6-AC20-49D8A0909C4F Q37947960-BF9C37A2-DEA4-4D95-B66C-9B85359CAD75 Q37993616-CDF90641-CA07-40E6-8794-E547816A805D Q38165517-934F174D-CB59-4C8C-AFBA-8FFD966BB272 Q38226022-280121E9-8475-4908-9B89-E1EE40BC323F Q38718096-0541540D-7E50-46FA-A8C6-0F7D8536E8D4

P2860

Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis

http://www.wikidata.org/entity/Q28343401

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@ast

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@en

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@nl

type

label

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@ast

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@en

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@nl

prefLabel

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@ast

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@en

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@nl

P1433

Q28343401-AA06144D-BD14-4AB6-A619-62DD2970AE16

P1476

Q28343401-84633190-F428-4890-884A-72D90EA3F2FB

P2093

Q28343401-49310193-A1C3-4FC9-9B87-5618CB1473F5

Q28343401-5C2EDA77-F0E3-4D84-BC43-42542EFBFE7E

Q28343401-86BD3B6F-58A0-431D-96F0-FC805A6F8D0E

P2860

Q28343401-07AE49E9-F78A-4AE2-BB2A-B9CB3CEC0093

Q28343401-131DF415-F109-4D4A-84A1-2788420024C7

Q28343401-17B9ECEB-DAE8-4632-A3C5-FED6AFBC2853

Q28343401-1F5AE138-CFBD-4B14-BCE6-E7323260EAE7

Q28343401-234BB880-A454-4B42-8423-5150B4F8517F

Q28343401-5FBF1E93-B8B4-4D51-8ADA-DF960535252D

Q28343401-6A7BD508-A30E-4D8B-B98F-C2CB1033E653

Q28343401-70E2BF3B-5792-466F-830F-FD5DD9BA70C0

Q28343401-743F41AB-7E0B-4403-8CC6-19D4C2A7F569

Q28343401-807F84D5-F8AA-4DC0-97E1-63A9E1A59553

P304

Q28343401-9261BF9B-CF0D-4337-8AE5-8DC27E595EA3

P31

Q28343401-F521F080-94F5-46DF-BA87-D52E85DEBDEC

P3181

Q28343401-D0CE0E85-456F-4147-97E3-9D959694CB3D

P356

Q28343401-74944516-5B64-43B9-A19D-1CFB5240131A

P407

Q28343401-87C6EFD3-C92B-439A-94E6-6A0CA7B51EED

P433

Q28343401-DBC764A8-2699-4661-82BB-8B2CBE89B9BB

P478

Q28343401-39C35404-F0A4-4E3B-92D4-78719BF1E479

P50

Q28343401-97C26A8F-5EEA-4F6C-A229-62E9AD382B53

P577

Q28343401-BD05DDF4-8033-4141-9A50-EF1A390AC1C2

P5875

Q28343401-5AEB3131-6D45-40FF-AF40-77F594AB4153

P698

Q28343401-351A615B-9D55-45DC-90BC-C945340AED52

P921

Q28343401-54F61DD7-1109-443E-990A-E343DACCD7B4

P932

Q28343401-C0CDC7FE-A51A-477E-BDC5-DC3E3EE7BC86

P3181

P356

JEM.189.12.1923

P1433

Journal of Experimental Medicine

P1476

Lipoxin (LX)A4 and aspirin-tri ...... s of a cytokine-chemokine axis

@en

P2093

C N Serhan

http://www.w3.org/2001/XMLSchema#string

M Hachicha

http://www.w3.org/2001/XMLSchema#string

N A Petasis

http://www.w3.org/2001/XMLSchema#string

P2860

Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor

Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions

Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors

Biologic basis for interleukin-1 in disease

Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse

5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors.

Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response.

Inhibition of angiogenesis by interleukin 4.

Tissue destruction by neutrophils.

Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction.

P304

1923-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4916207

http://www.w3.org/2001/XMLSchema#string

P356

10.1084/JEM.189.12.1923

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

189

http://www.w3.org/2001/XMLSchema#string

P50

P577

1999-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12922300

http://www.w3.org/2001/XMLSchema#string

P698

10377187

http://www.w3.org/2001/XMLSchema#string

P921

P932

2192964

http://www.w3.org/2001/XMLSchema#string